美国 · SEC FORM 4
DYNAVAX TECHNOLOGIES CORP
DVAX · — · CIK 0001029142 · Healthcare
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-08-22 · Myers Scott Dunseth.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
Form 4 申报证据
55 transaction lines in the latest 365-day window; 353 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-10 | Deep Track Biotechnology Master Fund, Ltd.; Deep Track Capital, LP; KROIN DAVID | U (U) | Common Stock, par value $0.001 per share | 15,726,349 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Sun Elaine D | D (D) | Common Stock - Restricted Stock Units | 29,865 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Spencer Ryan | U (U) | Common Stock | 379,620 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-10 | Deep Track Biotechnology Master Fund, Ltd.; Deep Track Capital, LP; KROIN DAVID | U (U) | Common Stock, par value $0.001 per share | 15,726,349 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Sun Elaine D | D (D) | Common Stock - Restricted Stock Units | 29,865 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Spencer Ryan | U (U) | Common Stock | 379,620 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Spencer Ryan | D (D) | Common Stock - Performance Stock Units | 301,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Spencer Ryan | 奖励／授予 (A) | Common Stock - Performance Stock Units | 301,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Slebir John L | U (U) | Common Stock | 69,634 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Slebir John L | D (D) | Common Stock - Performance Stock Units | 92,424 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Slebir John L | 奖励／授予 (A) | Common Stock - Performance Stock Units | 92,424 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | SILVERNAIL LAUREN P | D (D) | Common Stock - Restricted Stock Units | 10,075 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Novack David F | U (U) | Common Stock | 63,334 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Novack David F | D (D) | Common Stock - Performance Stock Units | 124,224 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Novack David F | 奖励／授予 (A) | Common Stock - Performance Stock Units | 124,224 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Myers Scott Dunseth | U (U) | Common Stock | 3,800 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Myers Scott Dunseth | D (D) | Common Stock - Restricted Stock Units | 31,204 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Metzinger Joseph Anthony | U (U) | Common Stock | 7,129 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | MacGregor Brent | D (D) | Common Stock - Restricted Stock Units | 21,829 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | MacDonald Kelly | U (U) | Common Stock | 60,204 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | MacDonald Kelly | D (D) | Common Stock - Performance Stock Units | 88,854 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | MacDonald Kelly | 奖励／授予 (A) | Common Stock - Performance Stock Units | 88,854 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | KISNER DANIEL L | U (U) | Common Stock | 1,500 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | KISNER DANIEL L | D (D) | Common Stock - Restricted Stock Units | 21,829 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | Emini Emilio | D (D) | Common Stock - Restricted Stock Units | 10,075 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-10 | CANO FRANCIS | D (D) | Common Stock - Restricted Stock Units | 42,663 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-15 | Novack David F | 卖出 (S) | Common Stock | 114,000 | USD 15.64 | USD 1,782,960 | SEC 申报 ↗ |
| 2026-01-15 | Novack David F | 期权行权／转换 (M) | Common Stock | 114,000 | USD 9.83 | USD 1,120,380 | SEC 申报 ↗ |
| 2025-12-24 | Spencer Ryan | 代扣税 (F) | Common Stock | 138,168 | USD 15.38 | USD 2,125,024 | SEC 申报 ↗ |
| 2025-12-24 | Slebir John L | 代扣税 (F) | Common Stock | 32,502 | USD 15.38 | USD 499,881 | SEC 申报 ↗ |
| 2025-12-24 | Novack David F | 卖出 (S) | Common Stock | 30,000 | USD 15.49 | USD 464,700 | SEC 申报 ↗ |
| 2025-12-24 | Novack David F | 期权行权／转换 (M) | Common Stock | 30,000 | USD 8.03 | USD 240,900 | SEC 申报 ↗ |
| 2025-12-24 | Novack David F | 代扣税 (F) | Common Stock | 48,107 | USD 15.38 | USD 739,886 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | DVAX |
| CIK | 0001029142 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 353 transaction lines from 2020-02-05 to 2026-02-10 2 P purchase lines · 89 S sale lines · 262 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.